Label expansion means that Illuccix is now approved to select patients, with progressive metastatic castration-resistant prostate cancer, for treatment with 177-Lu vipivotide tetraxetan, the only PSMA-targeted lutetium therapy registered in Canada.
With this breaking news .. could this have a domino effect ??
1: Helping thousands of Canadians, this must be a significant Commercial advantage for Telix, with the ever increasing awareness of
Illuccix globally, now to market in Canada, earning immediate revenue, !!
2: Plus surely momentum is gathering approval pace as mention by mnbvcxz12345 to obtaining further Country approvals !!
Could by chance all these pending approvals now final happen, as 2024 closes out ???
Label expansion means that Illuccix is now approved to select...
-
- There are more pages in this discussion • 2,328 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$25.75 |
Change
0.240(0.94%) |
Mkt cap ! $8.709B | |||
| Open | High | Low | Value | Volume |
| $25.51 | $26.25 | $25.51 | $31.79M | 1.227M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 116 | $25.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $25.80 | 1607 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| TLX (ASX) Chart |